MeSH D000230 - adenocarcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D002277:Carcinoma
D000230:
Adenocarcinoma
D000077192:Adenocarcinoma of lung
0 Companies
0 Drugs
Success rate
D000231:Papillary adenocarcinoma
0 Companies
0 Drugs
Success rate
D002276:Carcinoid tumor
D002285:Intraductal carcinoma noninfiltrating
0 Companies
0 Drugs
Success rate
D002288:Mucinous adenocarcinoma
0 Companies
0 Drugs
Success rate
D002292:Renal cell carcinoma
D002293:Scirrhous adenocarcinoma
0 Companies
0 Drugs
Success rate
D002822:Choriocarcinoma
D003528:Adenoid cystic carcinoma
0 Companies
0 Drugs
Success rate
D003536:Cystadenocarcinoma
0 Companies
0 Drugs
Success rate
D006528:Hepatocellular carcinoma
D010145:Extramammary paget disease
D011648:Ovine pulmonary adenomatosis
0 Companies
0 Drugs
Success rate
D018262:Clear cell adenocarcinoma
0 Companies
0 Drugs
Success rate
D018263:Follicular adenocarcinoma
0 Companies
0 Drugs
Success rate
D018266:Sebaceous adenocarcinoma
0 Companies
0 Drugs
Success rate
D018267:Acinar cell carcinoma
0 Companies
0 Drugs
Success rate
D018268:Adrenocortical carcinoma
D018269:Endometrioid carcinoma
0 Companies
0 Drugs
Success rate
D018273:Islet cell carcinoma
D018275:Lobular carcinoma
0 Companies
0 Drugs
Success rate
D018277:Mucoepidermoid carcinoma
0 Companies
0 Drugs
Success rate
D018278:Neuroendocrine carcinoma
0 Companies
0 Drugs
Success rate
D018279:Signet ring cell carcinoma
0 Companies
0 Drugs
Success rate
D018280:Skin appendage carcinoma
0 Companies
0 Drugs
Success rate
D018281:Cholangiocarcinoma
D044584:Ductal carcinoma
0 Companies
0 Drugs
Success rate
D057090:Eccrine porocarcinoma
0 Companies
0 Drugs
Success rate
D065311:Adenocarcinoma in situ
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Docetaxel | Docetaxel Teva | 2010-01-26 | |||
| Mylan | Docetaxel | Docetaxel Mylan | 2012-01-31 | |||
| Sanofi | Docetaxel | Taxotere | 1995-11-27 | |||
| Hospira | Mitomycin | Mitomycin | 1995-11-29 | |||
| Bristol Myers Squibb | Mitomycin | Mutamycin | 1982-01-01 | |||
| Accord Healthcare | Docetaxel | Docetaxel Accord | 2012-05-22 | |||
| Mitomycin | Mitomycin | 1998-04-30 | ||||
| Hikma Pharmaceuticals | Mitomycin | Mitomycin | 1995-04-19 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
84%102/122
Phase 2
28%55/197
Phase 3
16%12/75
Approved: 3Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use